RAMP1 and neoplasm: Blocking the CGRP–RAMP1 axis attenuates this immunomodulatory action of the nervous system on CD8+ T cells, thereby safeguarding the anti-tumour immunity of the host (Extended Data Fig. 12) and providing potential therapeutic opportunities by interrupting pro-cancerous neuro–immune links.